Pet insurance provider Trupanion (NASDAQ: TRUP) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 12.3% year on year to $384 million. Its GAAP profit of $0.11 per share was 37.5% above analysts’ consensus estimates.
Is now the time to buy Trupanion? Find out by accessing our full research report, it’s free.
Trupanion (TRUP) Q1 CY2026 Highlights:
- Revenue: $384 million vs analyst estimates of $380 million (12.3% year-on-year growth, 1.1% beat)
- Pre-tax Profit: $5.96 million (1.6% margin)
- EPS (GAAP): $0.11 vs analyst estimates of $0.08 (37.5% beat)
- Market Capitalization: $1.09 billion
“The gap between the cost of veterinary care and what pet parents can reasonably plan for continues to widen,” said Margi Tooth, Chief Executive Officer and President of Trupanion.
Company Overview
Born from a vision to help pet owners avoid economic euthanasia when faced with expensive veterinary bills, Trupanion (NASDAQ: TRUP) provides medical insurance for cats and dogs through data-driven, vertically-integrated products priced specifically for each pet's unique characteristics.
Revenue Growth
Insurers earn revenue three ways. The core insurance business itself, often called underwriting and represented in the income statement as premiums earned, is one way. Investment income from investing the “float” (premiums collected upfront not yet paid out as claims) in assets such as fixed-income assets and equities is the second way. Fees from various sources such as policy administration, annuities, or other value-added services is the third. Luckily, Trupanion’s revenue grew at an incredible 22.1% compounded annual growth rate over the last five years. Its growth beat the average insurance company and shows its offerings resonate with customers.
We at StockStory place the most emphasis on long-term growth, but within financials, a half-decade historical view may miss recent interest rate changes, market returns, and industry trends. Trupanion’s annualized revenue growth of 13.1% over the last two years is below its five-year trend, but we still think the results suggest healthy demand. 
This quarter, Trupanion reported year-on-year revenue growth of 12.3%, and its $384 million of revenue exceeded Wall Street’s estimates by 1.1%.
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
Key Takeaways from Trupanion’s Q1 Results
It was good to see Trupanion beat analysts’ EPS expectations this quarter. We were also happy its revenue narrowly outperformed Wall Street’s estimates. Zooming out, we think this was a solid print. The stock traded up 2.9% to $24.65 immediately after reporting.
Trupanion may have had a good quarter, but does that mean you should invest right now? If you’re making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here (it’s free).
